Gabelli Reiterates a Buy Rating on ICU Medical

By Ryan Adsit

Gabelli analyst Jennie Tsai reiterated a Buy rating on ICU Medical (NASDAQ: ICUI) today. The company’s shares closed yesterday at $166.65.

According to, Tsai is a 4-star analyst with an average return of 15.8% and a 65.4% success rate. Tsai covers the Healthcare sector, focusing on stocks such as K2M Group Holdings, Globus Medical, and Abbott Labs.

ICU Medical has an analyst consensus of Moderate Buy, with a price target consensus of $180.

The company has a one year high of $176.50 and a one year low of $120.15. Currently, ICU Medical has an average volume of 142.1K.

Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. Last month, Vivek Jain, the Chairman & CEO of ICUI sold 100,000 shares for a total of $17,079,386.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ICU Medical, Inc. develops, manufactures and sells medical devices used in infusion therapy, oncology and critical care applications. It operates through the following segments: Infusion Therapy, Critical Care, and Oncology.